Poseida Therapeutics aims for $115m stock market launch to f...

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR

Mixed results for Roche drugs in prostate cancer and COVID-1...

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug achieved only one of its targets and its inflammatory

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer. 

Xtandi takes fight to prostate cancer rivals with survival d...

AZ and MSD's Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient